

# Review on Alzheimer Disease

**Akash Popatrao Kale, Ms. Pooja Bhonde, Dr. Gajanan Sanap**

LBYP College of Pharmacy, Pathri, Chh. Sambhaji Nagar, Maharashtra, India  
 akkikale3302@gmail.com

**Abstract:** The most frequent cause of dementia, Alzheimer's disease, is a major global health concern that affects both individuals and society as a whole. This overview first discusses the current state of knowledge regarding the epidemiology, genetics, pathology, and pathophysiology of Alzheimer's disease before moving on to the disease's clinical manifestation and available treatments. Lastly, the article explores how novel therapeutic approaches are being developed with the goal of shifting from treatment to prevention in light of our growing understanding of Alzheimer aetiology, which includes the identification of a prolonged preclinical phase.

**Keywords:** EHR system.

## REFERENCES

- [1]. Alzheimer Europe. Dementia in Europe Yearbook 2019: estimating the prevalence of dementia in Europe. 2020. [https://www.alzheimereurope.org/content/download/19\\_5515/1457520/file/FINAL%2005707%20Alzheimer%20Europe%20yearbook%202019.pdf](https://www.alzheimereurope.org/content/download/19_5515/1457520/file/FINAL%2005707%20Alzheimer%20Europe%20yearbook%202019.pdf) (accessed Jan 24, 2021).
- [2]. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer's disease. Lancet 2016; 388: 505–17.
- [3]. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734–46.
- [4]. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–17.
- [5]. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003; 26: 81–104.
- [6]. Mortimer JA, Snowdon DA, Markesberry WR. Head circumference, education and risk of dementia: findings from the Nun Study. J Clin Exp Neuropsychol 2003; 25: 671–79.
- [7]. Alzheimer's Disease International. World Alzheimer Report 2018. The state of the art of dementia research: new frontiers. September, 2018. <https://www.alzint.org/u/WorldAlzheimerReport2018.pdf> (accessed Sept 9, 2020).
- [8]. Wu YT, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time—current evidence. Nat Rev Neurol 2017; 13: 327– 39.
- [9]. Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther 2016; 8: 23.
- [10]. De Strooper B, Karvanen E. The cellular phase of Alzheimer's disease. Cell 2016; 164: 603–15.
- [11]. Koper MJ, Van Schoor E, Ospitalieri S, et al. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease. Acta Neuropathol 2020; 139: 463–84.
- [12]. www.chatgpt.com
- [13]. Downs M, Turner S, Bryans M, et al. Effectiveness of educational interventions in improving detection and management of dementia in primary care: cluster randomised controlled study. BMJ 2006; 332: 692–96.
- [14]. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med 2004; 10 (suppl): S34–41.
- [15]. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306: 821–27.
- [16]. Kumar,A.; Singh, A. A review on Alzheimer's disease pathophysiology and its management: An update. Pharmacol. Rep. 2015, 67, 195–203. [CrossRef]



**IJARSCT**

**International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)**

**IJARSCT**

**ISSN (Online) 2581-9429**

**Impact Factor: 7.53**

**International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal**

**Volume 4, Issue 1, January 2024**

- [17]. Furtado, D.; Björnalm, M.; Ayton, S.; Bush, A.I.; Kempe, K.; Caruso, F. Overcoming the blood-brain barrier: The role of nanomaterials in treating neurological diseases. *Adv. Mater.* 2018, 30, 1801362. [CrossRef] [PubMed]
- [18]. Li, A.; Tyson, J.; Patel, S.; Patel, M.; Katakam, S.; Mao, X.; He, W. Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease. *Front. Bioeng. Biotechnol.* 2021, 9, 672594. [CrossRef] [PubMed]
- [19]. Sood, S.; Jain, K.; Gowthamarajan, K. Intranasal therapeutic strategies for management of Alzheimer's disease. *J. Drug Target.* 2014, 22, 279–294. [CrossRef] [PubMed]
- [20]. Agarwal, M.; Alam, M.R.; Haider, M.K.; Malik, M.; Kim, D.-K. Alzheimer's Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology. *Nanomaterials* 2021, 11, 59. [CrossRef]

